Merck's Q3 earnings call highlighted strong performance, particularly in KEYTRUDA and GARDASIL.  Management expressed confidence in the company's ability to continue strong growth, supported by the expanded KEYTRUDA label for earlier-stage cancers and the promising results of sotatercept.  Guidance was narrowed upward, reflecting a more optimistic view and significant progress with ADCs.

[1]
